Lake Street Downgrades Surmodics to Hold, Announces $43 Price Target
$SRDX
Medical/Dental Instruments
Health Care
Lake Street analyst Brooks O'Neil downgrades Surmodics (NASDAQ:SRDX) from Buy to Hold and announces $43 price target.
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 6/13/2023 | $36.00 | Hold → Buy | Needham |
| 2/13/2023 | Buy → Hold | Needham | |
| 2/4/2022 | $70.00 → $58.00 | Buy | Needham |
| 11/10/2021 | $76.00 → $70.00 | Buy | Needham |
| 9/8/2021 | $68.00 → $76.00 | Buy | Needham |
4 - SURMODICS INC (0000924717) (Issuer)
4 - SURMODICS INC (0000924717) (Issuer)
4 - SURMODICS INC (0000924717) (Issuer)
Surmodics, Inc. (NASDAQ:SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today reported financial results for its fourth quarter and fiscal year ended September 30, 2024. Fourth Quarter Fiscal 2024 Financial Summary Total Revenue of $33.2 million, an increase of 19% year-over-year Total Revenue excluding SurVeil™ drug-coated balloon ("DCB") license fee revenue(1) of $31.3 million, an increase of 17% year-over-year GAAP net loss of $(3.4) million, compared to net income of $6.7 million in the prior-year period Adjusted EBITDA(2) of $4.4 million, compared to $1.7 million in the prior-year period Fiscal 2024 Financial Summa
Surmodics, Inc. (NASDAQ:SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today reported financial results for its third quarter ended June 30, 2024. Third Quarter Fiscal 2024 Financial Summary Total Revenue of $30.3 million, compared to $52.5 million in the prior-year period which included $24.6 million in license fee revenue recognized upon receipt of a $27.0 million milestone payment associated with obtaining FDA premarket approval of the SurVeil™ drug-coated balloon ("DCB") Total Revenue excluding SurVeil DCB license fee revenue(1) of $29.2 million, an increase of 10% year-over-year GAAP net loss of $(7.6) million, co
Announces Commercial Launch of Two New Thrombectomy Devices for the Venous and Arterial Vasculatures: Pounce™ Venous and Pounce LP (Low Profile) Surmodics, Inc. (NASDAQ:SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today reported financial results for its second quarter ended March 31, 2024, and updated financial guidance for its fiscal year ending September 30, 2024. Second Quarter Fiscal 2024 Financial Summary Total Revenue of $32.0 million, an increase of 18% year-over-year Total Revenue excluding SurVeil™ drug-coated balloon ("DCB") license fee revenue(1) of $30.9 million, an increase of 19% year-over-year GAAP
Needham upgraded Surmodics from Hold to Buy and set a new price target of $36.00
Needham downgraded Surmodics from Buy to Hold
Needham reiterated coverage of Surmodics with a rating of Buy and set a new price target of $58.00 from $70.00 previously
10-K - SURMODICS INC (0000924717) (Filer)
8-K - SURMODICS INC (0000924717) (Filer)
DEFA14A - SURMODICS INC (0000924717) (Filer)
Effective June 1, 2024, the new agreement allows Premier members, at their discretion, to take advantage of special pricing and terms pre-negotiated by Premier for Surmodics Pounce and Pounce Venous Thrombectomy Systems.
Surmodics (NASDAQ:SRDX) has been analyzed by 5 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish. The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 2 1 2 0 0 Last 30D 0 0 0 0 0 1M Ago 1 1 2 0 0 2M Ago 1 0 0 0 0 3M Ago 0 0 0 0 0 The 12-month price targets, analyzed by analysts, offer insights with an average target of $49.4, a high estimate of $71.00, and a low estimate of $43.00. Experiencing a 16.27% decline, the current average is
Barrington Research analyst Michael Petusky downgrades Surmodics (NASDAQ:SRDX) from Outperform to Market Perform.
SC 13G/A - SURMODICS INC (0000924717) (Subject)
SC 13G/A - SURMODICS INC (0000924717) (Subject)
SC 13G/A - SURMODICS INC (0000924717) (Subject)
Surmodics, Inc. (NASDAQ:SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today reported financial results for its fourth quarter and fiscal year ended September 30, 2024. Fourth Quarter Fiscal 2024 Financial Summary Total Revenue of $33.2 million, an increase of 19% year-over-year Total Revenue excluding SurVeil™ drug-coated balloon ("DCB") license fee revenue(1) of $31.3 million, an increase of 17% year-over-year GAAP net loss of $(3.4) million, compared to net income of $6.7 million in the prior-year period Adjusted EBITDA(2) of $4.4 million, compared to $1.7 million in the prior-year period Fiscal 2024 Financial Summa
Early subset analysis of 60 patients with acute, subacute, or chronic symptoms of limb ischemia demonstrated 96.8% procedural flow restoration, with 81.7% of subjects not receiving additional thromboemboli removal treatment post Pounce™ System use. Surmodics, Inc. (NASDAQ:SRDX), a leading provider of medical device and in vitro diagnostic technologies to the health care industry, today announced that early results of a subset of 60 real-world acute, subacute, and chronic limb ischemia patients from its PROWL registry study were presented by Dr. Dean Ferrera at the 36th Annual TCT Symposium in Washington, D.C. PROWL is an open-label, retrospective, multi-center, U.S. registry of the Surmod
The Pounce™ Thrombectomy Platform can now be used to remove clot from peripheral arteries as small as 2mm up to as large as 10 mm in diameter, broadening the platform's clinical utility and significantly expanding its addressable market Surmodics, Inc. (NASDAQ:SRDX), a leading provider of medical device and in vitro diagnostic technologies, today announced it has received U.S. Food and Drug Administration (FDA) 510(k) clearance for its Pounce™ XL Thrombectomy System. The Pounce XL Thrombectomy System is indicated for the non-surgical removal of thrombi and emboli from the peripheral arterial vasculature in vessels 5.5–10 mm in diameter, making it suitable for iliac, femoral, and other art
KORU Medical Systems, Inc. (NASDAQ:KRMD) ("KORU Medical" or the "Company"), a leading medical technology company focused on the development, manufacturing, and commercialization of innovative and easy-to-use specialty subcutaneous infusion solutions that improve quality of life for patients, today announced the appointment of Andrew D. C. LaFrence as its Chief Financial Officer, effective July 10, 2023. Andy LaFrence joins KORU Medical bringing over 39 years of finance and accounting experience, including a track record of successfully executing and influencing growth-oriented business and M&A strategies, scaling businesses, developing and managing a global team of finance and accounting